Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer Academic Article uri icon

Overview

MeSH Major

  • Benzimidazoles
  • Iodine Radioisotopes
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • Thyroid Neoplasms

abstract

  • Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease. (Funded by the American Thyroid Association and others; ClinicalTrials.gov number, NCT00970359.).

publication date

  • February 14, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3615415

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1209288

PubMed ID

  • 23406027

Additional Document Info

start page

  • 623

end page

  • 32

volume

  • 368

number

  • 7